IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients See more here
Read More
IVIEW Therapeutics Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Trial of IVW-1001 for Dry Eye Disease See more here
Read More
iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease See more here
Read More
IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024 See more here
Read More
iVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease See more here
Read More
iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis See more here
Read More
IView Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID) See more here
Read More
IView-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA See more here
Read More
IView Therapeutics Closes its A round financing to move forward IView-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis See more here
Read More
IView Therapeutics was awarded SBIR Innovative grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID) See more here
Read More